US court confirms protection for Pfizer's Lyrica until 2018, hitting ANDA challenges
This article was originally published in Scrip
Executive Summary
Pfizer secured patent protection through to the end of 2018 for Lyrica (pregabalin) on 19 July when a US federal court judge said that the patents licensed from Northwestern University were valid and infringed by Teva Pharmaceuticals' and other manufacturers' US abbreviated new drug applications (ANDAs) for a generic formulation of the blockbuster pain drug.